XFOR Share Price Performance
US$4.00
0.98 (32.45%)
60.0% undervalued intrinsic discount
US$10.00
Fair Value
Price US$4.00
AnalystLowTarget US$10.00
AnalystConsensusTarget US$8.00
AnalystHighTarget US$13.00
Fair ValueUS$10.00
Share Pricen/a
X4 Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 19 Fair Values set on narratives written by author
XFOR Community Narratives
AN
Fair Value
·Fair Value US$10 60.0% undervalued intrinsic discount
Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$8 50.0% undervalued intrinsic discount
US Launch And EMA Approval Will Expand Global Reach
0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AN
Fair Value
·Fair Value US$13 69.2% undervalued intrinsic discount
Rising Rare Disease Awareness And Precision Medicine Will Expand Access
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Intensifying Trial Risks Will Hobble Returns Yet Open Global Potential
Key Takeaways Reliance on a single drug and competitive pressures from new therapies create significant risks to X4's future growth, profitability, and market share. Ongoing financial losses, regulatory challenges, and capital constraints threaten shareholder value and may delay the company's expansion into new markets.Read more
AN
US$10
60.0% undervalued intrinsic discount
Fair Value
Profit Margin
12.92%
Future PE
127.21x
Price in 2029
US$12.38
Rising Rare Disease Awareness And Precision Medicine Will Expand Access
Key Takeaways Strong trial results, physician demand, and broad label opportunities could drive faster adoption, revenue growth, and larger market access than currently projected. Strategic cost controls, greater diagnostic momentum, and supportive healthcare trends position X4 for improved profitability, pricing power, and long-term value creation.Read more
AN
US$13
69.2% undervalued intrinsic discount
Fair Value
Profit Margin
12.87%
Future PE
70.79x
Price in 2029
US$16.05
US Launch And EMA Approval Will Expand Global Reach
Key Takeaways The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence. Successful trials and restructuring efforts anticipate improved profitability and financial sustainability while targeting broader patient populations.Read more
AN
US$8
50.0% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
61.38x
Price in 2028
US$9.9
Trending Discussion
Recently Updated Narratives
AN
XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential
Fair Value: US$10 60.0% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside
Fair Value: US$13 69.2% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential
Fair Value: US$8 50.0% undervalued intrinsic discount
9 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
X4 Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.06
- 81.82%
- -1,106.30%
- 45.4%
About XFOR
- Founded
- n/a
- Employees
- 45
- CEO
- WebsiteView website
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
